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Objectives We sought to evaluate the clinical outcomes with a novel platinum chromium everolimus-eluting stent (PtCr-EES)
compared with a predicate cobalt chromium everolimus-eluting stent (CoCr-EES) in patients undergoing percuta-
neous coronary intervention (PCI).
Background Randomized trials have demonstrated an excellent safety and efficacy profile for the CoCr-EES. The PtCr-EES uses the
identical antiproliferative agent and polymer but with a novel platinum chromium scaffold designed for enhanced
deliverability, vessel conformability, side-branch access, radiopacity, radial strength, and fracture resistance.
Methods A total of 1,530 patients undergoing PCI of 1 or 2 de novo native lesions were randomized at 132 worldwide
sites to CoCr-EES (n  762) or PtCr-EES (n  768). The primary endpoint was the 12-month rate of target lesion
failure (TLF), the composite of target vessel-related cardiac death, target vessel-related myocardial infarction
(MI), or ischemia-driven target lesion revascularization (TLR) in the per-protocol population (patients who re-
ceived 1 assigned study stent), powered for noninferiority.
Results The 12-month rate of TLF in the per-protocol population occurred in 2.9% versus 3.4% of patients assigned to
CoCr-EES versus PtCr-EES, respectively (difference: 0.5%, 95% confidence interval: 1.3% to 2.3%, pnoninferiority 
0.001, psuperiority  0.60). By intention-to-treat, there were no significant differences between CoCr-EES and PtCr-
EES in the 12-month rates of TLF (3.2% vs. 3.5%, p  0.72), cardiac death or MI (2.5% vs. 2.0%, p  0.56), TLR
(1.9% vs. 1.9%, p  0.96), or Academic Research Consortium definite or probable stent thrombosis (0.4% vs.
0.4%, p  1.00).
Conclusions In this large-scale, prospective, single-blind randomized trial, a novel PtCr-EES was noninferior to the predicate
CoCr-EES for TLF, with nonsignificant differences in measures of safety and efficacy through 12-month follow-up
after PCI. (A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System
[PROMUS Element] for the Treatment of up to Two De Novo Coronary Artery Lesions: NCT00823212) (J Am
Coll Cardiol 2011;57:1700–8) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.02.016a consultant to Medtronic. Dr. Teirstein reports having received research grants,
honoraria, and consulting fees from Boston Scientific, Abbott Laboratories, Cordis,
and Medtronic. Dr. Meredith reports serving on the scientific advisory boards for and
receiving honoraria from Boston Scientific. Dr. Farah reports receiving honoraria
from Boston Scientific and Abbott Vascular. Dr. Dubois reports serving on the
scientific advisory board for Boston Scientific. Dr. Feldman reports serving on the
scientific advisory board for and receiving honoraria from Boston Scientific. Drs.
Allocco and Dawkins report being full-time employees and stockholders of Boston
Scientific. All other authors have reported that they have no relationships to disclose.From the *Columbia University Medical Center/New York-Presbyterian Hospital
and the Cardiovascular Research Foundation, New York, New York; †Scripps Clinic,
Division of Cardiovascular Diseases, La Jolla, California; ‡MonashHEART, South-
ern Health, Monash Medical Centre, Clayton, Victoria, Australia; §Clinique Pasteur,
Toulouse, France; UZ Gasthuisberg, Leuven, Belgium; ¶Munroe Regional Medical
Center, Ocala, Florida; #Ziekenhuis Oost Limburg, Genk, Belgium; **Tokyo
Women’s Medical University Hospital, Shinjuku, Tokyo, Japan; and ††Boston
Scientific Corporation, Natick, Massachusetts. A complete list of the study organi-
zation and participating sites and investigators from the PLATINUM trial may be
found in the Online Appendix. Dr. Stone reports serving on the scientific advisory
boards for and receiving honoraria from Boston Scientific and Abbott Vascular and is
Manuscript received February 14, 2011; revised manuscript received February 28,
2011, accepted February 28, 2011.

a
d
b
r
w
v
b
b
t
d
t
s
q
e
t
p
w
g
o
c
d
s
p
1701JACC Vol. 57, No. 16, 2011 Stone et al.
April 19, 2011:1700–8 A Novel Everolimus-Eluting Coronary StentSince the introduction of first-generation drug-eluting
stents (DES), advances in stent technology have continued
to improve the clinical outcomes for patients undergoing
percutaneous coronary intervention (PCI). Specifically, the
cobalt chromium everolimus-eluting stent (CoCr-EES)
(manufactured as XIENCE V by Abbott Vascular, Santa
Clara, California, also distributed as PROMUS by Boston
Scientific, Natick, Massachusetts) has been shown in a
series of randomized trials to reduce the rates of angio-
graphic and clinical restenosis, myocardial infarction (MI),
and stent thrombosis compared with a widely used
paclitaxel-eluting stent (1–4). Recently, a novel stent based
on a new metal alloy has been developed, the platinum
chromium everolimus-eluting stent (PtCr-EES) (manufac-
tured as PROMUS Element by Boston Scientific) (5,6),
which uses the same durable, biocompatible, inert fluoro-
copolymer and antiproliferative agent (7) as the predicate
CoCr-EES but with a modified scaffold designed to provide
improved deliverability, vessel conformability, side-branch
access, radiopacity, radial strength, and fracture resistance
(Fig. 1, Table 1). The PtCr-EES and CoCr-EES provide
comparable everolimus release kinetics, arterial tissue levels,
and vascular responses in a noninjured porcine coronary
artery model (8). The vascular responses to the PtCr-EES
were assessed in 73 patients in whom follow-up angiogra-
phy at 9 months was performed after PCI of a single
coronary lesion with reference vessel diameter (RVD) 2.5
to 4.25 mm and lesion length 24 mm (9). The angio-
graphic in-stent late loss was 0.17  0.25 mm, similar to
that previously reported with the CoCr-EES in the SPIRIT
First trial (A Clinical Evaluation of an Investigational
Device. The Abbott XIENCE V Everolimus Eluting Cor-
onary Stent System in the Treatment of Patients With de
Novo Native Coronary Artery Lesions) (0.10 0.21 mm at
6 months and 0.24  0.27 mm at 1 year), the SPIRIT II
trial (0.11  0.27 mm at 6 months), and the SPIRIT III
trial (0.16  0.41 mm at 8 months) (3,4,10,11). By
intravascular ultrasound, the percentage volume obstruction
with PtCr-EES at 9-month follow-up was 7.2 6.2%, also
comparable to that reported with the CoCr-EES (8.0 
10.4% and 10  7% at 6 and 12 months, respectively, from
the SPIRIT First trial; 2.5  4.7% at 6 months in the
SPIRIT II trial, and 6.9 6.4% at 8 months in the SPIRIT
III trial) (1,2,10,11).
To further assess the clinical safety and efficacy of the
PtCr-EES, we performed the PLATINUM (A Prospective,
Randomized, Multicenter Trial to Assess an Everolimus-
Eluting Coronary Stent System [PROMUS Element] for
the Treatment of up to Two De Novo Coronary Artery
Lesions), a large-scale, international, multicenter, prospec-
tive, single-blind randomized trial in which the PtCr-EES
was compared with the CoCr-EES in patients undergoing
PCI. The present report describes the principal analyses
from the pivotal PLATINUM trial. tMethods
Enrollment criteria. Patients
18 years of age with stable or
unstable angina pectoris or doc-
umented silent ischemia were
considered for enrollment. Pa-
tients requiring PCI during the
index procedure of 1 or 2 de novo
native coronary artery target le-
sions with RVD 2.5 to 4.25 mm,
lesion length 24 mm, and di-
ameter stenosis50% to100%
with Thrombolysis In Myocar-
dial Infarction flow grade 2 or 3
(by visual estimate) were eligible
for inclusion. If only 1 target
lesion was to be randomized, an
additional nontarget lesion in a
different vessel could be treated
before the target lesion, and the
patient would still qualify as long
as PCI of the nonstudy lesion
was angiographically successful
and uncomplicated. Principal
clinical exclusion criteria were
acute or recent MI; left ventric-
ular ejection fraction (LVEF)30%; prior or planned organ
transplant; recent or scheduled chemotherapy; autoimmune
disease or use of immunosuppressive therapy; platelet count
100,000 or 700,000 cells/mm3; white blood cell count
3,000 cells/mm3; liver disease, estimated creatinine clear-
nce 50 ml/min (Cockcroft-Gault formula), or need for
ialysis; active peptic ulcer or gastrointestinal bleeding,
leeding diathesis or coagulopathy, warfarin use, or will
efuse blood transfusions; stroke or transient ischemic attack
ithin 6 months or any permanent neurologic defect; target
essel treatment with atherectomy, laser, or cutting balloon
efore stent placement; any planned PCI or coronary artery
ypass graft after the index procedure (lesions in nonstudy
arget vessels could have been treated 24 h before ran-
omization); previous treatment with intracoronary brachy-
herapy; known allergy to any of the components of the
tudy stent or study medications that could not be ade-
uately pre-medicated; comorbidity that might reduce life
xpectancy to 24 months; participation in another inves-
igational drug or device trial that has not reached its
rimary endpoint; and inability or unwillingness to comply
ith all protocol-required procedures. Additional angio-
raphic exclusion criteria included lesion location in an
stial or left main location or in or through a bypass graft
onduit; true bifurcation lesion (side branch 2.0 mm in
iameter by visual estimate or with a significant ostial
tenosis); excessive tortuosity, angulation, or calcification
roximal to or within the lesion; or presence of thrombus in
Abbreviations
and Acronyms
ARC  Academic Research
Consortium
CI  confidence interval
CK-MB  creatine kinase-
myocardial band
CoCr-EES  cobalt
chromium everolimus-
eluting stent
DES  drug-eluting stent(s)
ITT  intention-to-treat
MI  myocardial infarction
PCI  percutaneous
coronary intervention
PtCr-EES  platinum
chromium everolimus-
eluting stent
RVD  reference vessel
diameter
TLF  target lesion failure
TLR  target lesion
revascularization
TVR  target vessel
revascularizationhe target vessel. The study was approved by the institu-
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center, and all eligible patients signed informed written
consent.
Protocol. After successful target lesion pre-dilation, ran-
domization was performed with an automated computer-
ized system in randomly permuted blocks of 2 or 4 patients.
Patients were randomized in 1:1 ratio to PtCr-EES or
Figure 1 Photograph of CoCr-EES and PtCr-EES
Photograph of the PROMUS cobalt chromium everolimus-eluting stent (CoCr-EES) (
everolimus-eluting stent (PtCr-EES) (right) (Boston Scientific, Natick, Massachuset
Comparison of Cobalt Chromium and Platinumhromium Everolimus-Eluting StentsTable 1 Compari on of Cobalt Chromium and PlatinumChromium Everolimus-Eluting Stents
Parameter CoCr-EES PtCr-EES
Drug Everolimus Everolimus
Polymer PBMA and
PVDF-HFP*
PBMA and
PVDF-HFP*
Polymer thickness (m) 7 7
Metal composition (%) Cobalt Chromium
(L605)
Platinum Chromium
Iron 3.0 max 37†
Platinum 0 33
Cobalt 52† 0
Chromium 20 18
Nickel 10 9
Tungsten 15 0
Molybdenum 0 2.63
Manganese 1.50 0.05 max
Strut width (m) 91 86
Strut thickness (m) 81 81
Nominal balloon pressure (atm) 9 12
Balloon rated burst pressure (atm) 16 18
Surface/artery ratio (%)‡§ 13.7 15.1
Scaffolding (mm)¶ 1.07 0.91
Radial strength (N/mm)§ 0.14 0.23
Stent recoil (%)§ 4.6 3.6
Conformability (N·mm)§# 0.30 0.09
Radiopacity/density (g/cm3) 9.1 9.9
Trackability (g·cm catheter)** 158 133
Data are for 3.0-mm stents. *Primer layer is poly (n-butyl methacrylate) (PBMA); drug matrix layer
is poly (vinylidene fluoride-co-hexafluoropropylene) (PVDF-HFP). †Balance value calculated from
nominal values of other elements. Elements listed as maximums (max) are taken at midpoint for
this calculation. ‡Percentage of artery wall area covered by the outer surface area of the stent.
§n  15 for platinum chromium everolimus-eluting stent (PtCr-EES); n  10 for cobalt chromium
everolimus-eluting stent (CoCr-EES). Average of the largest circle to fit in each cell. ¶n  5 for
tCr-EES; n  10 for CoCr-EES. #Conformability, a measure of the bending moment of the stent,
escribes ability of a stent to match the natural curvature of a vessel without causing vessel
traightening; a lower value reflects better conformability. **16-mm PtCr-EES and 18-mm CoCr-
ES, n 10/group; assessed bymeasuring the amount of work required to pass the device througha tortuous artery model; a lower value (less work) indicates better trackability.
N/mm  Newtons/millimeter; N·mm  Newton millimeters.CoCr-EES, stratified by the presence or absence of medi-
cally treated diabetes mellitus, by the intent to treat 1 versus
2 target lesions, and by study site. Patients were considered
enrolled upon randomization. Both stent types were avail-
able in diameters of 2.5 to 4.0 mm; available lengths were
12, 20, and 28 mm for PtCr-EES and 12, 18, and 28 mm
for CoCr-EES. The operator performing the procedure was
not blinded to the study stent, but patients and hospital
caregivers remained blinded.
The PCI was performed with unfractionated heparin,
enoxaparin, or bivalirudin as per local practice, and glyco-
protein IIb/IIIa inhibitors were permitted per investigator
discretion. Loading doses of aspirin (300 mg p.o. recom-
mended) and clopidogrel (300 mg p.o. required) were
required in patients not taking these medications 72 h
before the index procedure. Post-PCI daily aspirin was
required indefinitely, with 162 to 325 mg p.o. daily recom-
mended for at least the first 6 months and 75 to 162 mg p.o.
daily thereafter. Clopidogrel 75 mg p.o. daily was required
for at least 6 months after stent placement in all patients and
for at least 12 months in those not at high risk of bleeding.
Ticlopidine was allowed in patients intolerant of clopi-
dogrel, and prasugrel was permitted in non-U.S. sites in
accordance with approved country-specific labeling.
After hospital discharge, clinical follow-up was scheduled
for 1 month and 6, 12, and 18 months and then annually
from 2 to 5 years. Repeat angiographic follow-up was
performed only for clinical indications. The primary end-
point was assessed at 1 year, the timing of the present
report.
Data management. Study monitors verified all case report
form data on-site. An independent Clinical Events Com-
mittee (CEC) blinded to study stent assignment adjudicated
all death, MI, target vessel revascularization (TVR), and
stent thrombosis events. An independent Data Safety and
Monitoring Committee evaluated all reported and adjudi-
cated adverse events at regular intervals, each time allowing
the study to continue unchanged. Angiographic data were
analyzed by an independent core angiographic laboratory.
Study organization and oversight committee membership
are provided in the Online Appendix.
Endpoints and definitions. The primary endpoint was the
nd the PROMUS Element platinum chromium
th stents are 3.0 mm in diameter. See text for details.left) a
ts). Bo12-month rate of target lesion failure (TLF), defined as the
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confirmed to have a noncardiac cause) related to the target
vessel, MI related to the target vessel, or ischemia-driven
target lesion revascularization (TLR). Myocardial infarction
was defined as: 1) the development of new Q waves in 2
leads lasting 0.04 s with creatine kinase-myocardial band
(CK-MB) or troponin levels elevated above normal; or 2) in
the absence of new Q waves, elevation of total CK levels
3 normal (peri-PCI) or 2 normal (spontaneous)
with elevated CK-MB, or troponin 3 normal (peri-
PCI) or 2 normal (spontaneous) plus at least 1 of the
following: 1) electrocardiographic changes indicative of new
ischemia (new ST-T changes or left bundle branch block);
2) imaging evidence of new loss of viable myocardium; or 3)
new regional wall motion abnormality. Similar criteria were
required for the diagnosis of MI after coronary artery bypass
graft surgery, with a CK-MB or troponin threshold of5
normal. Ischemia-driven TLR or TVR was defined as
revascularization of the target lesion or vessel with the
stenosis 50% by quantitative coronary angiography if
associated with clinical or functional ischemia (ischemic
symptoms, electrocardiographic changes, or positive func-
tional study), or stenosis 70% by quantitative coronary
angiography without documented ischemia. Additional
clinical endpoints included target vessel failure (defined as
the composite of cardiac death, MI, or ischemia-driven
TVR); the components of TLF and target vessel failure;
stent thrombosis defined according to the definite or prob-
able Academic Research Consortium (ARC) criteria (12),
subclassified as acute (24 h), subacute (24 h to 30 days),
and late (30 days to 1 year); technical success (successful
delivery and deployment of the study stent to the target
vessel, without balloon rupture or stent embolization); and
clinical procedural success (visually assessed lesion diameter
stenosis30% with Thrombolysis In Myocardial Infarction
flow grade 3, without in-hospital MI, TVR, or cardiac
death).
Sample size determination and statistical methods. The
randomized trial was powered for noninferiority testing of
PtCr-EES compared with CoCr-EES for the primary
endpoint of 12-month TLF. A 2-group Farrington-
Manning test was used to test the 1-sided hypothesis of
noninferiority in differences with a noninferiority margin
(delta) of 3.5%. A p value 0.05 would indicate noninfe-
riority of PtCr-EES and would correspond to the upper
limit of the 1-sided 95% confidence interval (CI) of the
difference not exceeding 3.5%. The trial had 89% power to
demonstrate noninferiority for TLF (accounting for an
expected 1-year attrition rate of 5%), assuming a 1-year
TLF rate of 5.5% for both stents (on the basis of the data
available at the time of study design for CoCr-EES from
the SPIRIT II and III trials [1,2]), with 766 patients
enrolled/treatment group.
Treatment groups were compared with a 2-sided chi-
square or Fisher exact test for categorical variables and
Student t test for continuous variables. The Kaplan-Meierproduct-limit method was used to estimate event rates for
time-to-event outcomes; data were compared with the
log-rank test. The primary endpoint was pre-specified to be
tested in the per-protocol population (patients receiving 1 or
more assigned study stents). All endpoints were also ana-
lyzed in the intention-to-treat (ITT) population (including
all patients who underwent randomization, regardless of
treatment actually received). All statistical analyses were
done with SAS software (version 8.2 or above, SAS Insti-
tute, Inc., Cary, North Carolina).
Results
Patient characteristics and procedural outcomes. Be-
tween January 27, 2009 and September 4, 2009, 1,530
patients were enrolled at 132 sites in the United States (n 
788), European Union (n  562), Japan (n  124), and
other Asia Pacific countries (n  56), and were randomized
to CoCr-EES (n  762) or PtCr-EES (n  768). The
baseline clinical and angiographic features of the random-
ized study groups were well-matched (Table 2). Mean
patient age was 63.5 years, 28.6% were women, 23.5% had
medically treated diabetes, and 24.4% presented with un-
stable angina. Multiple target lesions were treated in 10.7%
of patients. The mean lesion RVD was 2.65 mm, and mean
lesion length was 12.7 mm. Procedural and angiographic
outcomes were also similar between the groups (Table 3),
although slightly more CoCr-EES than PtCr-EES were
used per lesion, and the maximum dilation pressure was
higher for PtCr-EES. Nonetheless, angiographic acute gain
and post-PCI target lesion luminal measures were not
significantly different between the 2 stent types.
Among patients randomized to CoCr-EES and PtCr-
EES, technical success was achieved in 98.8% and 99.4% of
patients, respectively (p  0.14), and clinical procedural
success was achieved in 98.2% and 98.3%, respectively (p 
0.83). Unplanned (bail-out) stenting was required in 75
patients (9.8%) treated with CoCr-EES (for procedural
complications [n  36], inadequate lesion coverage [n 
26], or other reasons [n  13]) compared with 45 patients
(5.9%) treated with PtCr-EES (for procedural complica-
tions [n  29], inadequate lesion coverage [n  11], or
other reasons [n  5]) (p  0.004). Other performance
measures were comparable between the groups.
Clinical outcomes. Patient flow in the study is shown in
Figure 2. Follow-up at 12 months was completed in 96.7%
of patients. Among patients randomized to CoCr-EES
versus PtCr-EES, aspirin was used by 99.6% and 98.7%,
respectively, at hospital discharge (p  0.053) and by 97.4%
and 97.6%, respectively, at 1 year (p  0.84). A thienopyri-
dine (clopidogrel, ticlopidine, or prasugrel) was used by
99.1% and 98.8% of CoCr-EES and PtCr-EES–assigned
patients, respectively, at the time of hospital discharge (p 
0.63) and in 89.4% and 90.9% of patients at 1 year,
1704 Stone et al. JACC Vol. 57, No. 16, 2011
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patient at discharge (in the PtCr-EES group) and by 6
patients in each group at 1 year.
The primary endpoint analysis appears in Figure 3. The
rate of TLF at 12 months in the per-protocol population
occurred in 2.9% of patients assigned to CoCr-EES and
3.4% of patients assigned to PtCr-EES (difference: 0.5%,
95% CI: 1.3% to 2.3%, psuperiority  0.60). The 1-sided
95% Farrington-Manning upper confidence bound was
2.13%, which is less than the pre-specified noninferiority
margin of 3.5%. As such, the primary endpoint of nonin-
feriority for PtCr-EES compared with CoCr-EES for TLF
at 12 months was met (pnoninferiority  0.001). Similarly, in
the ITT population, the 12-month rate of TLF was
nonsignificantly different between CoCr-EES and PtCr-
EES (3.2% vs. 3.5%, respectively; difference: 0.3%, 95% CI:
1.5% to 2.2%, pnoninferiority  0.0009, psuperiority  0.72)
(Fig. 4).
Additional 12-month outcomes in the ITT population
appear in Table 4. There were no significant differences
detected in any safety or efficacy measure between the stent
types. The 1-year rate of TLR was 1.9% for both groups
(p  0.96). ARC definite or probable stent thrombosis
through 1 year of follow-up occurred in only 3 patients
(0.4%) in each group (1 acute, 2 subacute, and 0 late
events with CoCr-EES; and 1 acute, 0 subacute, and 2
Baseline Clinical and Angiographic Features ofTable 2 Baseline Clinical and Angiographic
CoCr-
(n  762 P
n  841 L
Demographic features
Age (yrs) 63.1 10
Male 542/762
Hypertension* 558/762
Hypercholesterolemia* 579/760
Diabetes* 191/762
Insulin treated 48/762
Current smoker 131/741
Prior myocardial infarction 160/760
Unstable angina 188/762
Number of target lesions, mean 1.10 0.3
1 684/762
2 77/762
3 1/762
Target vessel
Left anterior descending 343/813
Left circumflex 216/813
Right 254/813
Target lesion measures
Reference vessel diameter, mm 2.63
Minimal lumen diameter, mm 0.74
Diameter stenosis, % 71.9
Lesion length, mm 12.5
Values are mean  SD or n/N (%). *Requiring medication.
Abbreviations as in Table 1.late events with PtCr-EES).Discussion
The principal findings from the present analysis, represent-
ing the pivotal 1-year outcomes from the multicenter,
multinational, prospective, randomized PLATINUM trial,
are that: 1) a novel PtCr-EES has been developed with
noninferior 12-month rates of TLF compared with the
predicate CoCr-EES; 2) clinical restenosis (ischemia-driven
TLR) within 1 year occurred infrequently and to a similar
degree with both stents in the patient population tested; and
3) both stents demonstrated an excellent safety profile, with
nonsignificantly different 12-month rates of cardiac death,
MI, and stent thrombosis.
Prior studies have demonstrated that, across a broad
cross-section of patients undergoing PCI, the CoCr-EES
results in low rates of TLF, a relatively stent-specific
composite measure of safety and efficacy. In large-scale
randomized trials, patients treated with the CoCr-EES
have been shown to have reduced 1-year rates of TLF,
TLR, MI, and stent thrombosis compared with the first-
generation paclitaxel-eluting stent (5,6) and nonsignifi-
cantly different 1-year rates of TLF, TLR, and MI but less
stent thrombosis compared with a second-generation
zotarolimus-eluting stent (13). The favorable results with
this device likely stem from the properties of its 3 main
components: the polymer, the drug, and the metallic stent
andomized Study Groupsres of the Randomized Study Groups
ts,
s)
PtCr-EES
(n  768 Patients,
n  853 Lesions) p Value
2) 64.1 10.3 (768) 0.09
) 550/768 (71.6) 0.83
) 544/767 (70.9) 0.32
) 598/765 (78.2) 0.36
) 169/768 (22.0) 0.16
59/768 (7.7) 0.29
) 158/751 (21.0) 0.10
) 160/761 (21.0) 0.99
) 185/767 (24.1) 0.80
2) 1.11 0.31 (768) 0.66
) 683/768 (88.9) 0.60
) 85/768 (11.1) 0.54
0/768 (0.0) 0.50
) 347/824 (42.1) 0.97
) 217/824 (26.3) 0.91
) 260/824 (31.6) 0.89
2.67 0.49 0.09
0.75 0.35 0.40
71.8 11.5 0.87
13.0 5.7 0.10the RFeatu
EES
atien
esion
.3 (76
(71.1
(73.2
(76.2
(25.1
(6.3)
(17.7
(21.1
(24.7
1 (76
(89.8
(10.1
(0.1)
(42.2
(26.6
(31.2
0.49
0.34
11.5
5.5itself. The thin (7 m), nonadhesive, durable and inert
r post-
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tant to platelet and thrombus deposition in blood-contact
applications (14,15), possibly contributing to resistance to
stent thrombosis. The polymer controls the release kinetics
of the everolimus such that approximately 80% of the drug
is released at 30 days, with none detectable after 120 days.
The dose density of everolimus (100 g/cm2) is lower than
with any comparable rapamycin-analogue DES. Finally, the
Figure 2 Patient Flow in the Randomized Trial
Abbreviations as in Figure 1.
Procedural and Angiographic Outcomes of the RTable 3 Procedural and Angiographic Outco
(n 
n 
Procedural variables
Stents/patient, n
Stents/target lesion, n
Maximum stent diameter/lesion (mm)
Maximum stent diameter/RVD ratio (mm)
Total stent length/lesion (mm)
Total stent length/lesion length ratio (mm)
Post-stent dilation performed 41
Maximum dilation pressure (atm)*
Glycoprotein IIb/IIIa inhibitors used 6
Non-target lesions treated 7
Fluoroscopy time (min)
Contrast used (cc)
Post-procedural results (per target lesion)
Reference vessel diameter (mm)
Minimum lumen diameter (mm)
In-stent
In-segment
Diameter stenosis, %
In-stent
In-segment
Acute gain, %
In-stent
In-segment
Values are mean  SD or n/N (%). *Pre-dilation, stent implantation, othin (81 m) CoCr stent struts facilitate rapid re-
endothelialization (16) and are fracture-resistant. Preclinical
studies have demonstrated more rapid coverage of the
CoCr-EES struts with functional endothelialization than
with other DES (17).
Through use of a more dense platinum chromium alloy
and a modified scaffold architecture, the PtCr-EES was
developed to further improve upon several of the mechanical
mized Study Groupsof the Randomized Study Groups
-EES
Patients,
Lesions)
PtCr-EES
(n  768 Patients,
n  853 Lesions) p Value
0.48 1.16 0.44 0.16
0.35 1.05 0.26 0.01
0.44 3.09 0.45 0.07
0.15 1.17 0.15 0.63
8.9 20.5 7.0 0.06
0.7 1.8 0.7 0.25
(49.3%) 425/853 (49.8%) 0.84
3.2 16.3 3.1 0.002
2 (8.1%) 56/768 (7.3%) 0.54
2 (9.3%) 69/768 (9.0%) 0.82
10.1 12.2 11.8 0.10
86 185 87 0.85
0.50 2.70 0.49 0.27
0.44 2.57 0.42 0.25
0.47 2.19 0.47 0.15
8.7 4.3 9.1 0.95
9.0 18.8 8.6 0.43
0.45 1.81 0.43 0.73
0.47 1.44 0.46 0.45
dilation balloon.andomes
CoCr
762
841
1.20
1.08
3.05
1.18
19.7
1.7
5/841
15.9
2/76
1/76
11.3
184
2.67
2.54
2.16
4.3
19.2
1.80
1.42
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enhance trackability, vessel conformability, side-branch ac-
cess, radiopacity, radial strength, and fracture resistance). A
paclitaxel-eluting version of this stent (TAXUS Element,
Boston Scientific) has previously been shown to have
noninferior clinical outcomes compared with the predicate
stainless steel TAXUS Express stent (18). A major design
goal for the PtCr-EES was to preserve the clinical safety
and efficacy profile of the CoCr-EES by maintaining the
same polymer thickness, everolimus concentration, and
pharmacokinetics present in the CoCr-EES while improv-
Figure 3 Primary Endpoint of TLF at 1 Year
Primary endpoint of target lesion failure (TLF) at 1 year for the per-protocol popula
Plot shows the difference in TLF at 1-year between the CoCr-EES and the test PtCr
the 1-sided 95% CI (red line). The p values for noninferiority and superiority testin
Figure 4 Time-to-Event Curves for the Primary Endpoint
of TLF in the ITT Population
The event rates presented here were calculated by Kaplan-Meier methodology
and compared with the log-rank test. Thus, the p value differs slightly from that
in the text and Table 4, which were calculated using categorical variables and
compared with the chi-square test. HR  hazard ratio; other abbreviations as in
Figures 1 and 3.ing acute performance. In this regard, comparable everoli-
mus release kinetics, arterial tissue levels, and vascular
responses have been reported for the PtCr-EES and CoCr-
EES in a noninjured porcine coronary artery model (8), and
in a prior nonrandomized clinical study the PtCr-EES was
found to have rates of angiographic in-stent and in-segment
late loss comparable to those of the CoCr-EES (9). The
current results from the large-scale PLATINUM random-
ized trial demonstrate noninferiority of the PtCr-EES to
the CoCr-EES for the composite safety and efficacy mea-
sure of TLF at 1 year, with nonstatistically significant
different rates present in death, MI, and TLR. Notably, the
0.4% 1-year rate of ARC definite or probable stent throm-
bosis in both groups in the present trial confirms the low
thrombosis rates reported with the EES in prior studies
(1–4,10,11,14). Thus, along with stainless steel and cobalt
chromium, platinum chromium may now be considered an
acceptable metal alloy for use in DES.
Although the rates of technical and clinical procedural
success achieved with the 2 stents were similar in the present
study, a higher rate of unplanned (bail-out) stenting was
observed with CoCr-EES compared with PtCr-EES. The
clinical relevance of this finding is uncertain. The present
study was not designed to evaluate whether the PtCr-EES
is indeed more deliverable, conformable, and/or more ra-
diopaque; affords better side-branch access; is more resistant
to recoil; and/or is more fracture resistant than the CoCr-
EES. These properties might be difficult to measure in
patients, because differences between devices that are de-
tectable on the bench might not be clinically relevant or
otherwise perceptible in vivo (19). Typically, extensive
rimary analysis) and the intention-to-treat (ITT) population (secondary analysis).
with the 2-sided confidence intervals (CIs) (black line) and the upper bound of
- and 2-sided, respectively. Abbreviations as in Figure 1.tion (p
-EES,
g are 1multicenter clinical experience in patients with complex
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stent deliverability and other ease-of-use characteristics.
Study limitations. The 1-year TLF rate with the control
oCr-EES (2.9% in the per-protocol population, and 3.2%
n the ITT population) was less than the 5.5% rate assumed
uring sample size estimation, which was based on prior
ata from the SPIRIT II and III trials. In the larger SPIRIT
V trial, in which slightly more complex lesions were
nrolled than in either of the earlier SPIRIT trials (or the
resent study), the 1-year TLF rate was only 4.2%, lower
han had previously been reported. As such, small absolute
ifferences in event rates between the PtCr-EES and
oCr-EES cannot be excluded by the present study. None-
heless, the observed 2-sided 95% CI of the difference in the
ate of 12-month TLF (1.3% to 2.3%) ensures that a large
bsolute difference in TLF between the 2 stent types is
nlikely in the lesions tested. Longer-term follow-up and in
ore complex lesions is required for a comprehensive
valuation between these 2 devices. In this regard, to meet
egulatory requirements, the SPIRIT and PLATINUM
rials excluded many high-risk patients, such as those with
cute or recent MI or visible thrombus, chronic total
cclusions, true bifurcations, and lesions in the left main
oronary artery or a saphenous vein graft. In contrast, in a
1-Year Clinical Outcomes in the ITT PopulationTable 4 1-Year Clinical Outcomes in the ITT Population
CoCr-EES
(n  762)
PtCr-EES
(n  768) p Value
All-cause death, MI, TVR 36/732 (4.9) 37/745 (5.0) 0.97
All-cause death or MI 22/732 (3.0) 18/745 (2.4) 0.49
All death 9/732 (1.2) 10/745 (1.3) 0.85
Cardiac death 5/732 (0.7) 7/745 (0.9) 0.58
Related to the TV 3/732 (0.4) 6/745 (0.8) 0.51
Not related to the TV 2/732 (0.3) 1/745 (0.1) 0.62
Noncardiac death 4/732 (0.5) 3/745 (0.4) 0.72
MI 13/732 (1.8) 8/745 (1.1) 0.25
Related to the TV 12/732 (1.6) 6/745 (0.8) 0.14
Not related to the TV 1/732 (0.1) 2/745 (0.3) 1.00
Q-wave MI 5/732 (0.7) 1/745 (0.1) 0.12
NonQ-wave MI 9/732 (1.2) 7/745 (0.9) 0.59
TVR, overall 21/732 (2.9) 20/745 (2.7) 0.83
TLR, overall 14/732 (1.9) 14/745 (1.9) 0.96
TLR, PCI 12/732 (1.6) 10/745 (1.3) 0.64
TLR, CABG 2/732 (0.3) 4/745 (0.5) 0.67
Non-TLR TVR, overall 8/732 (1.1) 7/745 (0.9) 0.77
Cardiac death or MI 18/732 (2.5) 15/745 (2.0) 0.56
Target lesion failure 23/727 (3.2) 26/742 (3.5) 0.72
Target vessel failure 29/727 (4.0) 31/742 (4.2) 0.85
Stent thrombosis
(ARC definite or
probable)
3/725 (0.4) 3/735 (0.4) 1.00
Definite 3/725 (0.4) 3/735 (0.4) 1.00
Probable 0/725 (0.0) 0/735 (0.0) —
Values are n/N (%).
ARC  Academic Research Consortium; CABG  coronary artery bypass graft; ITT  intention-
to-treat; MImyocardial infarction; PCI percutaneous coronary intervention; TLR target lesion
evascularization; TV target vessel; TVR target vessel revascularization; other abbreviations as
n Table 1.arge-scale randomized trial in which these patients wereactively enrolled, the 1-year rate of TLF with the CoCr-
EES was greater (8.2%) than observed in the present study
(13). In the future, adoption of the so-called “all-comers”
design for regulatory approval stent trials would permit
low-frequency but clinically relevant differences between
devices to become statistically apparent (or more reliably be
excluded), while maintaining reasonable sample size.
Conclusions
In summary, a novel PtCr-EES has been developed and
shown to have noninferior 1-year clinical outcomes com-
pared with the predicate CoCr-EES in patients undergoing
PCI of up to 2 noncomplex de novo native coronary artery
lesions.
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APPENDIX
For complete list of the study organization and participating sites
and investigators, please see the online version of this article.
